Johan A. Dobber
Amsterdam, NH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Fixed-duration ibrutinib-venetoclax with MRD-guided ibrutinib-obinutuzumab intensification in first-line chronic lymphocytic leukaemia (HOVON 158/NEXT STEP): primary analysis of a multicentre, open-label, phase 2 trial.
Journal: The Lancet. Haematology
Published: June 17, 2025
Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia.
Journal: Blood cancer journal
Published: March 02, 2023
Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial.
Journal: The Lancet. Oncology
Published: February 05, 2022
Discriminating between Waldenström macroglobulinemia and marginal zone lymphoma using logistic LASSO regression.
Journal: Leukemia & lymphoma
Published: December 28, 2021
Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial.
Journal: The Lancet. Haematology
Published: November 12, 2021
Changes in primary and secondary hemostasis in patients with CLL treated with venetoclax and ibrutinib.
Journal: Leukemia & lymphoma
Published: September 01, 2020
Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia.
Journal: Blood
Published: August 10, 2020
Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy: results from the HOVON 109 study.
Journal: Experimental hematology
Published: June 10, 2020
Last Updated: 09/26/2026